Loading...
Market
Which age group will show the most significant response to BioNTech's mRNA lung cancer vaccine in the UK trial by end of 2024?
2
Resolution / Starting Odds
Under 40 • 25%
40-59 • 25%
60-79 • 25%
80 and above • 25%
Official trial results published by BioNTech or peer-reviewed medical journals
Story
67-Year-Old First in UK to Receive BioNTech's mRNA Lung Cancer Vaccine
Aug 23, 2024, 09:16 AM
A pioneering lung cancer vaccine trial has commenced in the UK, marking a significant milestone in cancer treatment. The trial involves a 67-year-old patient who is the first in the UK to receive this experimental vaccine. This trial is part of a larger, world-first initiative being conducted across seven countries. The vaccine, developed by German company BioNTech, uses mRNA technology to prime the immune system to recognize and combat lung cancer cells. This development comes amid a concerning rise in lung cancer cases among young, non-smokers.
View original story
Similar markets
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Yes • 50%
No • 50%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
12-17 years • 25%
18-29 years • 25%
30-49 years • 25%
50+ years • 25%
65-74 • 25%
75-84 • 25%
85 and older • 25%
Immunocompromised individuals • 25%
Yes • 50%
No • 50%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
UK • 14%
USA • 14%
Germany • 14%
France • 14%
Japan • 14%
Australia • 14%
Other • 14%
0-2 countries • 25%
3-5 countries • 25%
6-8 countries • 25%
9 or more countries • 25%